You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Moodys
AstraZeneca
Boehringer Ingelheim
Harvard Business School
Mallinckrodt

Last Updated: February 25, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,307,417


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,307,417 protect, and when does it expire?

Patent 10,307,417 protects RELISTOR and is included in one NDA.

This patent has forty-nine patent family members in thirty countries.

Summary for Patent: 10,307,417
Title:Oral formulations and lipophilic salts of methylnaltrexone
Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
Inventor(s): Shah; Syed M. (Delray Beach, FL), Diorio; Christopher Richard (Campbell Hall, NY), Ehrnsperger; Eric C. (New City, NY), Meng; Xu (San Diego, CA), Al Shareffi; Kadum A. (Greensboro, NC), Cohen; Jonathan Marc (Monroe, NY)
Assignee: Wyeth, LLC (Madison, NJ)
Application Number:16/219,681
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,307,417
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Device; Dosage form;

Drugs Protected by US Patent 10,307,417

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Salix RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,307,417

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 080491   Start Trial
Australia 2011224275   Start Trial
Brazil 112012022873   Start Trial
Canada 2789798   Start Trial
Chile 2012002192   Start Trial
China 102918039   Start Trial
China 107308125   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
AstraZeneca
Moodys
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.